BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 25854168)

  • 21. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma.
    Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ
    Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of MDM2 Overexpression in Ameloblastomas with
    Tosios KI; Kalogirou EM; Koutlas IG
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overexpression of MDM2 protein in ameloblastomas as compared to adenomatoid odontogenic tumor.
    Krishna A; Kaveri H; Naveen Kumar RK; Kumaraswamy KL; Shylaja S; Murthy S
    J Cancer Res Ther; 2012; 8(2):232-7. PubMed ID: 22842367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of CD90 and P75NTR stem cell markers in ameloblastomas: a possible role in their biological behavior.
    Silva FP; Dias A; Coelho CA; Guerra EN; Marques AE; Decurcio DA; Mantesso A; Cury SE; Silva BS
    Braz Oral Res; 2016 Oct; 30(1):e109. PubMed ID: 27737362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcriptional profiles of SHH pathway genes in keratocystic odontogenic tumor and ameloblastoma.
    Gurgel CA; Buim ME; Carvalho KC; Sales CB; Reis MG; de Souza RO; de Faro Valverde L; de Azevedo RA; Dos Santos JN; Soares FA; Ramos EA
    J Oral Pathol Med; 2014 Sep; 43(8):619-26. PubMed ID: 24930892
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aberrant beta-catenin expression and adenomatous polyposis coli gene mutation in ameloblastoma and odontogenic carcinoma.
    Siriwardena BS; Kudo Y; Ogawa I; Tilakaratne WM; Takata T
    Oral Oncol; 2009 Feb; 45(2):103-8. PubMed ID: 18486530
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
    do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
    Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA damage response activation and cell cycle dysregulation in infiltrative ameloblastomas: A proposed model for ameloblastoma tumor evolution.
    Diniz MG; Guimarães BVA; Pereira NB; de Menezes GHF; Gomes CC; Gomez RS
    Exp Mol Pathol; 2017 Jun; 102(3):391-395. PubMed ID: 28454892
    [No Abstract]   [Full Text] [Related]  

  • 29. The Mutational Profile of Unicystic Ameloblastoma.
    Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
    J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The importance of BRAF-V600E mutation to ameloblastoma metabolism.
    Duarte-Andrade FF; Silva AMB; Vitório JG; Canuto GAB; Costa SFS; Diniz MG; Fernandes AP; de Toledo JS; André LC; Gomes CC; Gomez RS; Fonseca FP
    J Oral Pathol Med; 2019 Apr; 48(4):307-314. PubMed ID: 30739334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-expression of hepatocyte growth factor and c-met in epithelial odontogenic tumors.
    Poomsawat S; Punyasingh J; Vejchapipat P; Larbcharoensub N
    Acta Histochem; 2012 Jul; 114(4):400-5. PubMed ID: 21855117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review.
    González-González R; López-Verdín S; Lavalle-Carrasco J; Molina-Frechero N; Isiordia-Espinoza M; Carreón-Burciaga RG; Bologna-Molina R
    World J Clin Oncol; 2020 Jan; 11(1):31-42. PubMed ID: 31976308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing pathogenic mutations in dental follicles as an attempt to identify early events in odontogenic tumours tumourigenesis.
    Coura BP; de Resende TAC; de Menezes VCB; Bernardes VF; de Sousa SF; Diniz MG; Gomez RS; Gomes CC
    Arch Oral Biol; 2020 May; 113():104523. PubMed ID: 31543246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF p.V600E status in epithelial areas of ameloblastoma with different histological aspects: Implications to the clinical practice.
    Sant'Ana MSP; Dos Santos Costa SF; da Silva MP; Martins-Chaves RR; Pereira TDSF; de Oliveira EM; Martínez Pedraza R; de Castro WH; Gomes CC; Gomez RS; Fonseca FP
    J Oral Pathol Med; 2021 May; 50(5):478-484. PubMed ID: 33377543
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High frequency of BRAF V600E mutations in ameloblastoma.
    Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
    J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenoid Ameloblastoma with BRAF p.V600E Mutation Revealing Ameloblastomatous Origin: A First Case Report.
    Noda Y; Sawada S; Sakagami T; Kojima Y; Higasa K; Tsuta K
    Head Neck Pathol; 2023 Sep; 17(3):788-792. PubMed ID: 37093491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adenoid ameloblastoma harbors beta-catenin mutations.
    Bastos VC; Coura BP; Guimarães LM; Fernandes BG; Chan AC; Vargas PA; Bastos-Rodrigues L; De Marco LA; Hellstein J; Thavaraj S; Wright JM; Odell EW; Gomez RS; Gomes CC
    Mod Pathol; 2022 Nov; 35(11):1562-1569. PubMed ID: 35840721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential expression of PEA3 in odontogenic cysts and tumors.
    Tun KM; Kitkumthorn N; Bumalee D; Arayapisit T; Lapthanasupkul P
    J Oral Pathol Med; 2023 Sep; 52(8):777-785. PubMed ID: 37549030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas.
    Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular defects in BRAF wild-type ameloblastomas and craniopharyngiomas-differences in mutation profiles in epithelial-derived oropharyngeal neoplasms.
    Bartels S; Adisa A; Aladelusi T; Lemound J; Stucki-Koch A; Hussein S; Kreipe H; Hartmann C; Lehmann U; Hussein K
    Virchows Arch; 2018 Jun; 472(6):1055-1059. PubMed ID: 29546640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.